Advancing novel nanoparticle-based treatments for ocular disease
Kala is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both the front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. Beyond ophthalmology, Kala’s MPP technology has potential applications in women’s reproductive health, respiratory and gastrointestinal diseases, and other indications.
Year Invested: 2009
Location: Waltham, Mass.